Get the Stockscreener App
11.80
3.57%
-0.24
Anbio Biotechnology stock is traded at $11.80, with a volume of 22,125.
It is down -3.57% in the last 24 hours and down -49.50% over the past month.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
See More
Previous Close:
$12.04
Open:
$12.21
24h Volume:
22,125
Relative Volume:
0.65
Market Cap:
$512.43M
Revenue:
$9.74M
Net Income/Loss:
$7.19M
P/E Ratio:
72.08
EPS:
0.1637
Net Cash Flow:
$2.25M
1W Performance:
-15.32%
1M Performance:
-49.50%
6M Performance:
-66.10%
1Y Performance:
-70.50%
1-Day Range:
$11.65
$13.69
1-Week Range:
$11.01
$13.69
52-Week Range:
$10.50
$55.65
Anbio Biotechnology Stock (NNNN) Company Profile
Name
Anbio Biotechnology
Sector
Industry
Phone
-
Address
-
Compare NNNN vs ISRG, BDX, MDLN, ALC, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NNNN
Anbio Biotechnology
|
11.68 | 528.45M | 9.74M | 7.19M | 2.25M | 0.1637 |
ISRG
Intuitive Surgical Inc
|
428.19 | 153.29B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
157.26 | 42.86B | 21.37B | 1.41B | 3.07B | 3.9437 |
MDLN
Medline Inc
|
42.84 | 36.15B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
66.88 | 33.32B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
218.80 | 31.68B | 5.54B | 1.52B | 1.74B | 10.37 |
Anbio Biotechnology Stock (NNNN) Latest News
Top 3 Health Care Stocks That May Rocket Higher In July - Benzinga
Top 3 health care stocks you'll regret missing in Q2 - MSN
Price to book forward of Anbio Biotechnology – NASDAQ:NNNN - TradingView
Price to earnings forward of Anbio Biotechnology – NASDAQ:NNNN - TradingView
Enterprise value to revenue forward of Anbio Biotechnology – NASDAQ:NNNN - TradingView
Price to earnings forward of Anbio Biotechnology Class A – FWB:N3B - TradingView
Anbio Biotechnology (NNNN) Stock Price Today - CoinMarketCap
NNNN PE Ratio & Valuation, Is NNNN Overvalued - Intellectia AI
Anbio Biotechnology (NNNN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Anbio Biotechnology (NNNN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Anbio Biotechnology Soars After Surprise Media Spotlight - TipRanks
Anbio Biotechnology (NNNN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Anbio Biotechnology (NNNN) Institutional Confidence - TradingKey
Anbio Biotechnology (NNNN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Anbio Biotechnology (NNNN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Top 3 Health Care Stocks You'll Regret Missing In Q2 - Benzinga
Anbio Biotechnology (NNNN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Anbio Biotechnology (NNNN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Anbio Biotechnology (NNNN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Anbio Biotechnology Soars as Geopolitics Ignite Rebound - TipRanks
Why Anbio Biotechnology Class A Shares Are Sliding - TipRanks
Anbio Biotechnology (NNNN) director ZHANG MICHAEL W.C files initial Form 3 - Stock Titan
Director David H. Hsu files initial Form 3 at Anbio Biotechnology (NNNN) - Stock Titan
Why Anbio Biotechnology Shares Keep Sinking Today - TipRanks
Anbio Biotechnology (NNNN) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Why Anbio Biotechnology Class A Shares Are Sinking - TipRanks
Anbio’s Stock Has Been On A Wild Run Since Its IPO - Finimize
Anbio Biotechnology (NNNN) Faces Sharp Pullback: Key Levels and Market Sentiment After 14.88% DeclinePercent Above MA - newsline.com
Anbio Biotechnology (NNNN) Drops 7.2% as Selling Pressure IntensifiesOpening Range Breakout - newsline.com
Why Anbio Biotechnology Class A Stock Is Sliding - TipRanks
Why Anbio Biotechnology NNNN Shares Are Surging Now - TipRanks
Why Anbio Biotechnology Shares Are Tumbling Today - TipRanks
Anbio Biotechnology Holds Steady Near $34.41 as Trading Volume Remains ModerateThrowback Trade - The Legal Advocate
Why Anbio Biotechnology Class A Shares Are Surging - TipRanks
Anbio Biotechnology (NNNN) Stock Forecast and Price Target 2026 - MarketBeat
NNNNAnbio Biotechnology Stock Price and Quote - Finviz
Anbio Biotechnology (NNNN) Holds Near Support as Selling Pressure ModeratesAAII Bearish - newsline.com
Assessing Anbio Biotechnology (NNNN) Valuation After Strong Recent Share Price Momentum - simplywall.st
Anbio Biotechnology (NNNN) Share Price Forecast & Price Target - Investing.com UK
Why Anbio Biotechnology Shares Are Tumbling Now - TipRanks
Anbio Biotechnology Shareholders Approve Sweeping Capital and Governance Changes - TipRanks
Control shifts as Anbio (NNNN) boosts Class B voting power - Stock Titan
Why Anbio Biotechnology Shares Won’t Stop Climbing - TipRanks
Uncovering 3 Undiscovered Gems in the US Market - Yahoo Finance
Top Hemab Therapeutics (COAG) Competitors 2026 - MarketBeat
TradingKey - TradingKey
Number of shareholders of Anbio Biotechnology – NASDAQ:NNNN - TradingView
Why Anbio Biotechnology Class A Shares Keep Sliding - TipRanks
Why are smart money investors paying attention to Anbio (NNNN)? (Momentum Fading) 2026-05-07Overvalued Stocks - Newser
Hemab Therapeutics Hldgs (COAG) Stock Analysis Report | Financials & Insights - Benzinga
Anbio Biotechnology Stock (NNNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.30%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):